COVID-19 Response: Local Logistics     National Effort       

COVID-19 Response: Local Logistics     National Effort

CARB-X Accelerator at C-CAMP

CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is the world's largest public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With up to US$500 million to invest, CARB-X funds the best science around the world to accelerate the development of new antibiotics, vaccines, diagnostics and other life-saving products. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent and treat life-threatening bacterial infections.

C-CAMP has been selected by CARB-X for its prestigious Global Accelerator Network (GAN), a league of 10 world-class organisations to combat anti-microbial resistance (AMR). C-CAMP is the only accelerator in the CARB-X GAN outside of USA and Europe. GAN will provide scientific, technical and business support to CARB-X-funded product developers around the world. The Network is a one-of-a-kind source of knowhow and expertise in antibacterial drug development, diagnostics, business strategy and other areas essential to driving innovation and accelerating CARB-X’s growing portfolio of early development research projects.

Through this partnership with CARB-X, C-CAMP will fast track the latest AMR related innovations and deep science technology.

NEWS! - CARB-X has announced funding call 2019 in four rounds - 

CARB-X is launching four new funding rounds to support the development of antibiotics, vaccines, diagnostics and other life-saving products targeting drug-resistant bacteria. Applications are invited from product developers around the world. 

The four rounds of the call for applications and deadlines are as below - 

  •         Round 1 - Non-traditional Approaches - June 3 - June10, 5pm ET 
  •         Round 2 - Vaccines & Biotherapeutics- July 8-July 15, 5pm ET
  •         Round 3 - Diagnostics - August 12 - August 19, 5pm ET
  •         Round 4 - Direct-acting small molecule antibiotics  - November 12 - November 19, 5pm ET

See for more details. For any questions, reach out to us for more info at